Zentalis price target lowered to $6 from $8 at Guggenheim

Guggenheim lowered the firm’s price target on Zentalis (ZNTL) to $6 from $8 and keeps a Buy rating on the shares after the company provided a comprehensive azenosertib update. Taken together, the firm believes the data show “clear” and consistent monotherapy clinical efficacy in Cyclin-E1-positive prOC patients across all three trials that “exceeds the regulatory bar for accelerated approval in a relatively large dataset,” the analyst tells investors.